Showing results (1051-1060 of 1,451) with videos related to

Sort By:
Pageof 146
Toxicological Sciences : an Official Journal of the Society of Toxicology|May 14, 2004
Chronic exposure to dibromoacetic acid, a water disinfection byproduct, diminishes primordial follicle populations in the rabbitK J Bodensteiner, H R Sawyer, C L Moeller, et al.
Journal of Applied Behavior Analysis|September 29, 2015
Relations between rate of negative reinforcement and the persistence of task completionPatrick W Romani, Joel E Ringdahl, David P Wacker, et al.
Genome Biology|January 27, 2012
Implications for health and disease in the genetic signature of the Ashkenazi Jewish populationSaurav Guha, Jeffrey A Rosenfeld, Anil K Malhotra, et al.
Behavioral and Brain Functions : BBF|October 20, 2005
COMT genetic variation confers risk for psychotic and affective disorders: a case control studyBirgit Funke, Anil K Malhotra, Christine T Finn, et al.
Pharmacopsychiatry|January 8, 2013
Predicting a 'combined treatment outcome' in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-beingD Naber, S Kollack-Walker, J Chen, et al.
Schizophrenia Research|June 29, 2021
Striatal functional connectivity in psychosis relapse: A hypothesis generating studyJose M Rubio, Todd Lencz, Anita Barber, et al.
The Journal of Clinical Psychiatry|March 7, 2019
Clinical Guidance on the Identification and Management of Treatment-Resistant SchizophreniaJohn M Kane, Ofer Agid, Marjorie L Baldwin, et al.
Journal of the American College of Clinical Pharmacy : JACCP|January 31, 2023
Nirmatrelvir-ritonavir treatment of COVID-19 in a high-risk patient population: A retrospective observational studyAnna M Kane, Erica M Keenan, Kasheng Lee, et al.
Neuropsychiatric Disease and Treatment|October 24, 2024
Introducing S.C.O.P.E.™ (Schizophrenia Clinical Outcome Scenarios and Patient-Provider Engagement), an Interactive Digital Platform to Educate Healthcare Professionals on Schizophrenia CareChristoph U Correll, Jose M Rubio, Leslie Citrome, et al.
Journal of Psychiatric Research|March 12, 2014
A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophreniaJoan H Q Shen, Yonggang Zhao, Sharon Rosenzweig-Lipson, et al.
Pageof 146